AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21552138
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri 1×10 colony-forming units twice daily for 4 weeks
Trial: 10933353
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus 20 mg/day simvastatin
Trial: 11831346
Drug: Passive jaw
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive jaw motion device therapy (Therabite)
Trial: 11831346
Drug: Wooden tongue
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wooden tongue depressors therapy (WTD)
Trial: 7741566
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler (MDI) with a valved holding chamber
Trial: 2048819
Drug: Budesonide, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, 800 micrograms twice a day
Trial: 7002706
Drug: Loperamide (4.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4.6 mg, 2.3 capsules)
Trial: 7002706
Drug: Codeine (103.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (103.5 mg, 2.3 capsules)
Trial: 7002706
Drug: Diphenoxylate (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenoxylate (12.5 mg, 2.5 capsules)
Trial: 28746324
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (CBT and pharmacotherapy)
Trial: 21259026
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise (AR: A + R)
Trial: 19275979
Drug: Internet administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internet administration of the Kansas City Cardiomyopathy Questionnaire (KCCQ)
Trial: 19275979
Drug: Internet administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internet administration of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Trial: 19275979
Drug: Internet administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internet administration of the Self-Care Heart Failure Index (SCHFI)
Trial: 19275979
Drug: Pen-and-paper administration
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pen-and-paper administration of the Kansas City Cardiomyopathy Questionnaire (KCCQ)
Trial: 19275979
Drug: Pen-and-paper administration
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pen-and-paper administration of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Trial: 19275979
Drug: Pen-and-paper administration
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pen-and-paper administration of the Self-Care Heart Failure Index (SCHFI)
Trial: 11332151
Drug: CEF14 (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF14 (chemotherapy regimen delivered every two weeks)
Trial: 11332151
Drug: CEF21 (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF21 (chemotherapy regimen delivered every three weeks)
Trial: 11332151
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of RT and CT
Trial: 8424300
Drug: Clonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3 mg orally)
Trial: 8424300
Drug: Lignocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine (1.5 mg.kg‐1 prior to induction)
Trial: 28591942
Drug: Sialidase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sialidase inhibitor N‐Acetyl‐2, 3‐dehydro‐2‐deoxyneuraminic acid (DANA)
Trial: 22383336
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide LAR (both doses)
Trial: 18801190
Drug: Standardized hypnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized hypnosis treatment with ten consecutive therapeutic sessions once a week, each lasting about 30 minutes, focusing on ego-strengthening, relaxation, releasing muscular tension, and increasing self-efficacy.
Trial: 18801190
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment during initial phase).
Trial: 12717603
Drug: Subcutaneous specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous specific immunotherapy with Der p/Der f
Trial: 2018441
Drug: Stanozolol 5
RxNorm normalized name: stanozolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanozolol 5 mg twice daily for 6 months
Trial: 2018441
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily for 6 months
Trial: 7114130
Drug: Progesterone implants
RxNorm normalized name: estradiol / progesterone Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone implants (6 pellets of 100 mg each)
Trial: 9738562
Drug: Raltitrexed (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed (3 mg/m2) once every 3 weeks
Trial: 9738562
Drug: 5-FU (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (400 mg/m2) plus LV (200 mg/m2) daily for 5 days every 4 weeks
Trial: 7972979
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg b.i.d. (sustained release tablets)
Trial: 2743632
Drug: Daily observed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily observed prophylaxis (DOP) and education
Trial: 2743632
Drug: Self‐administered anti‐tuberculous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered anti‐tuberculous prophylaxis (SAP) and education
Trial: 4851604
Drug: Amiloride 10
RxNorm normalized name: amiloride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 10 mg daily in the postoperative period
Trial: 29459184
Drug: Urinary cadmium
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary cadmium at 10 years (highest tertile: 0.30-2.6 μg/L)
Trial: 22698919
Drug: 3.0 pmol/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 pmol/kg/min human BNP-32 administered as a continuous infusion during 4 h
Trial: 18662627
Drug: Fast-track group
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-track group (FTG) with remifentanil and spinal analgesia (low-dose morphine and clonidine)
Trial: 1869800
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg aspirin per day for two days
Trial: 29183698
Drug: Customized porous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized porous titanium implants
Trial: 29183698
Drug: Customized PEEK
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized PEEK implants
Trial: 20166160
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) treatment on one side of the face, four treatments at 3- to 4-week intervals.
Trial: 16314784
Drug: Tacrolimus plus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus plus low-dose short-term steroids
Trial: 11923325
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of ramoplanin
Trial: 11923325
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ramoplanin
Trial: 11923325
Drug: Ramoplanin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramoplanin (all doses)
Trial: 11923325
Drug: Ramoplanin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramoplanin (all doses) with antibiotics against anaerobic organisms
Trial: 11923325
Drug: Ramoplanin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramoplanin (all doses) avoiding antibiotics against anaerobic organisms
Trial: 1977079
Drug: Standard-treatment group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-treatment group (zidovudine 250 mg every four hours)
Trial: 1977079
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (zidovudine 200 mg every four hours for four weeks, then 100 mg every four hours)
Trial: 28697497
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of aflibercept (IVA) 2.0 mg every 2 months after 3 initial monthly doses
Trial: 16926252
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) administration in men
Trial: 16926252
Drug: Testosterone plus
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone plus GH administration in men
Trial: 16926252
Drug: Sex steroid(s)
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex steroid(s) alone in women (estrogen/progesterone)
Trial: 16926252
Drug: Sex steroid(s)
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex steroid(s) combined with GH in women
Trial: 14741071
Drug: nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nateglinide 120 mg t.i.d. for 5 days
Trial: 9107259
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of at least two drugs
Trial: 9107259
Drug: Substitution or
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitution or addition of at least two new agents
Trial: 9107259
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of two nucleoside analogues plus a third agent
Trial: 9107259
Drug: Two protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two protease inhibitors
Trial: 3004189
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet (500 mg cholesterol/day)
Trial: 3004189
Drug: Low-cholesterol diet
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-cholesterol diet (250 mg/day)
Trial: 3004189
Drug: Added-bran diet
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Added-bran diet (30 g/day)
Trial: 31952982
Drug: Urate-lowering therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urate-lowering therapy (ULT) with Allopurinol
Trial: 31952982
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment of asymptomatic and non-severe hyperuricemia
Trial: 27141626
Drug: Forearm-injection (forearm-)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forearm-injection (forearm-)
Trial: 27141626
Drug: Jiaji (EX-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiaji (EX-B 2)-injection (EX-B 2-1)
Trial: 27141626
Drug: Zusanli-injection (ST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zusanli-injection (ST 36-1)
Trial: 2941929
Drug: 2.5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 micrograms recombinant hepatitis B vaccine
Trial: 31541597
Drug: Intradermal PRP
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal PRP injection and excimer laser
Trial: 29738424
Drug: Vaginal estradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol tablet (10μg)
Trial: 27238895
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy along with NSAIDs for 12 weeks
Trial: 16483967
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy in aCL positive primiparae (49 subjects)
Trial: 14587042
Drug: Intermittent anti-D
RxNorm normalized name: anti-D (rh) immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent anti-D treatment
Trial: 14587042
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care (glucocorticoid treatment followed by splenectomy)
Trial: 29217387
Drug: Standard duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard duration of elastic compression therapy (24 months)
Trial: 27099242
Drug: Topical local
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical local anaesthesia
Trial: 27099242
Drug: Water-based gel
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based gel (placebo)
Trial: 25897826
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus rmhTNF (265 patients)
Trial: 25897826
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (264 patients)
Trial: 11823767
Drug: Paroxetine initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine initiation at 20 mg/d for 1 month
Trial: 11823767
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment continued for at least 1 month
Trial: 11823767
Drug: Any antipanic
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antipanic medication at 3 months
Trial: 10782562
Drug: Atorvastatin (generally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (generally 10 mg/day)
Trial: 8746920
Drug: Buprenorphine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (2 mg daily)
Trial: 8746920
Drug: Buprenorphine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (8 mg daily)
Trial: 23666554
Drug: Trifluoromethylphenylpiperazine (TFMPP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluoromethylphenylpiperazine (TFMPP) 50 or 60 mg
Trial: 23666554
Drug: Benzylpiperazine (BZP)
RxNorm normalized name: cinnamido benzylpiperidinyl ethoxypropylbenzamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzylpiperazine (BZP) 200 mg + Trifluoromethylphenylpiperazine (TFMPP) 100 mg + 30 mg
Trial: 21489843
Drug: Group intervention
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group intervention comprising seminars only (group G; n=26)
Trial: 21489843
Drug: Group intervention
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group intervention (group G)
Trial: 19681868
Drug: Avizafone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avizafone (20 mg)
Trial: 19681868
Drug: Diazepam (11.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (11.3 mg)
Trial: 19681868
Drug: Avizafone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avizafone (20 mg) with atropine (2 mg) and pralidoxime (350 mg)
Trial: 11720430
Drug: GM-CSF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF with dacarbazine (5 microg kg(‐1), bid, day 2 to day 19 every 21 days and DTIC: 800 mg m(‐2), day 1 of each cycle)
Trial: 9164318
Drug: Highly active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly active antiretroviral treatment (HAART) regimens
Trial: 3667007
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline suspension
Trial: 3667007
Drug: Slow-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release theophylline tablets
Trial: 25523492
Drug: Inhalation sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation sedation with nitrous oxide/oxygen (N2O/O2)
Trial: 21953275
Drug: Selumetinib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (75 mg) taken with food
Trial: 21953275
Drug: Selumetinib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (75 mg) taken after fasting for at least 10 hours
Trial: 10509320
Drug: Primary combined‐modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary combined‐modality therapy
Trial: 10509320
Drug: Preoperative combined‐modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative combined‐modality therapy
Trial: 10509320
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of radiation (INT 0123 trial)
Trial: 21816056
Drug: Probiotic combination
RxNorm normalized name: PROBIOTIC COMBINATION CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic combination (Bifidobacterium infantis, Streptococcus thermophilus and Bifidobacterium lactis)
Trial: 9385482
Drug: Sparfloxacin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 400 mg orally once followed by 200 mg orally daily for 10 days (n = 168)
Trial: 9385482
Drug: Cefaclor 500
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 500 mg orally every 8 hours for 10 days (n = 162)
Trial: 7961014
Drug: Continuous low
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low dose rate iridium implants following 50 Gy whole breast irradiation
Trial: 7961014
Drug: Dose rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose rate (mean 0.57, range 0.26-0.89 Gy/h)
Trial: 27746539
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg intrathecal levobupivacaine with 25 μg fentanyl followed by epidural top‐ups of 14 ml of levobupivacaine 0.125% with fentanyl 30 μg
Trial: 27746539
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intrathecal ropivacaine with 25 μg fentanyl followed by epidural top‐ups of 14 ml of ropivacaine 0.2% with fentanyl 30 μg
Trial: 23908479
Drug: Heat-treated zoster
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-treated zoster vaccine (ZVHT)
Trial: 10950766
Drug: Saquinavir soft-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir soft-gel capsules (SQVsgc)
Trial: 10950766
Drug: Saquinavir hard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir hard capsules (SQVhc)
Trial: 8979093
Drug: No antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antihypertensive therapy
Trial: 1468245
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sodium hyaluronate in 2 ml phosphate buffer for 5 weeks
Trial: 1468245
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sodium hyaluronate in 2 ml phosphate buffer for 5 weeks + 0.4 mg dexamethasone phosphate
Trial: 373254
Drug: Tagamet (cimetidine)
RxNorm normalized name: cimetidine Oral Tablet [Tagamet]
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tagamet (cimetidine) 1 g daily (3x200 mg after meal and 400 mg in the evening) for 20 days
Trial: 7877646
Drug: Adjuvant combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant combination chemotherapy (cyclophosphamide, methotrexate, and fluorouracil) for 12 monthly cycles
Trial: 2172161
Drug: Benazepril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (20 mg once or 5 mg four times at 6-hour intervals)
Trial: 23818692
Drug: 1.36 g
RxNorm normalized name: FERROUS SULFATE 381.36 g in 454 g TOPICAL POWDER [Blood Stop Powder]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.36 g L-carnitine + 80 g carbohydrate (Carnitine)
Trial: 23818692
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g carbohydrate (Control)
Trial: 18822917
Drug: Conventional liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional liver protecting therapy (Control)
Trial: 12950604
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy (omeprazole 4 x 40 mg and amoxicillin 4 x 750 mg for 14 days)
Trial: 12950604
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (omeprazole 2 x 20 mg, bismuthcitrate 4 x 107 mg, metronidazole 4 x 500 mg and tetracycline 4 x 500 mg for 14 days)
Trial: 8829931
Drug: Nasal inhalation
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal inhalation of sevoflurane 5%
Trial: 8829931
Drug: Oral inhalation
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation of sevoflurane 5%